Edition:
United Kingdom

InVivo Therapeutics Holdings Corp (NVIV.OQ)

NVIV.OQ on NASDAQ Stock Exchange Global Market

0.52USD
16 Feb 2018
Change (% chg)

$-0.00 (-0.02%)
Prev Close
$0.52
Open
$0.51
Day's High
$0.54
Day's Low
$0.50
Volume
9,183
Avg. Vol
38,622
52-wk High
$4.55
52-wk Low
$0.45

Latest Key Developments (Source: Significant Developments)

InVivo Therapeutics Announces Latest Results From INSPIRE
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - InVivo Therapeutics Holdings Corp ::INVIVO THERAPEUTICS ANNOUNCES LATEST RESULTS FROM INSPIRE AND PROVIDES UPDATE ON PROPOSED CLINICAL PATH FORWARD.INVIVO THERAPEUTICS HOLDINGS - 19 PATIENTS IMPLANTED WITH NEURO-SPINAL SCAFFOLD;3 PATIENTS DIED WITHIN 2 WEEKS OF IMPLANTATION​ IN STUDY.INVIVO THERAPEUTICS HOLDINGS CORP - ‍16 EVALUABLE PATIENTS HAVE NOW ALL REACHED SIX-MONTH PRIMARY ENDPOINT VISIT IN STUDY​.INVIVO THERAPEUTICS - ‍DOES NOT ANTICIPATE REOPENING ENROLLMENT IN INSPIRE,EXPECTS TO PROVIDE ADDITIONAL CLARITY ON CLINICAL PATH FORWARD IN Q2 2018​.  Full Article

InVivo Therapeutics Announces Executive Management And Board Changes
Monday, 18 Dec 2017 

Dec 18 (Reuters) - InVivo Therapeutics Holdings Corp ::INVIVO THERAPEUTICS ANNOUNCES EXECUTIVE MANAGEMENT AND BOARD CHANGES.INVIVO THERAPEUTICS HOLDINGS CORP - ‍RICHARD TOSELLI, NAMED ACTING CHIEF EXECUTIVE OFFICER​.INVIVO THERAPEUTICS HOLDINGS CORP - ‍ TOSELLI REPLACES MARK PERRIN, WHO HAS RESIGNED AS CEO AND CHAIRMAN OF INVIVO'S BOARD OF DIRECTORS​.INVIVO THERAPEUTICS HOLDINGS CORP - ‍ TOSELLI WILL CONTINUE TO SERVE IN HIS CAPACITY AS INVIVO'S CHIEF MEDICAL OFFICER​.INVIVO THERAPEUTICS HOLDINGS CORP - ANN MERRIFIELD WAS APPOINTED AS CHAIR OF BOARD OF DIRECTORS​.  Full Article

InVivo Therapeutics reports Q3 loss per share $0.28
Monday, 30 Oct 2017 

Oct 30 (Reuters) - InVivo Therapeutics Holdings Corp :InVivo Therapeutics provides business update and reports 2017 third quarter financial results.Q3 adjusted loss per share $0.19 excluding items.Q3 loss per share $0.28.  Full Article

Invivo Therapeutics Holdings Q2 loss per share $0.16
Thursday, 4 Aug 2016 

Invivo Therapeutics Holdings Corp : Invivo Therapeutics reports 2016 second quarter financial results and business update . Q2 loss per share $0.16 . Q2 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S .Q2 adjusted loss per share $0.18 excluding items.  Full Article

InVivo receives investigational testing authorization from Health Canada
Wednesday, 13 Jul 2016 

InVivo Therapeutics Holdings Corp :Receives investigational testing authorization from Health Canada.  Full Article

Invivo Therapeutics says Christina Morrison appointed as chairwoman of audit committee
Wednesday, 8 Jun 2016 

Invivo Therapeutics Holdings Corp - :Effective June 7, 2016, Christina Morrison was also appointed to serve as chairwoman of audit committee of board.  Full Article

Invivo Therapeutics Holdings Q1 loss per share $0.24
Friday, 6 May 2016 

Invivo Therapeutics Holdings Corp : Invivo Therapeutics reports 2016 first quarter financial results and business update .Q1 loss per share $0.24.  Full Article

InVivo Therapeutics Holdings Corp announces pricing of public offering of common stock
Tuesday, 15 Mar 2016 

InVivo Therapeutics Holdings Corp:Says pricing of an underwritten public offering of 3,733,333 units at a public offering price of $7.50 per unit.Says Each unit consists of one share of common stock and .50 of a warrant to purchase a share of common stock at an exercise price of $10.00 per share.  Full Article

InVivo Therapeutics Holdings Corp. Announces Proposed Public Offering
Monday, 14 Mar 2016 

InVivo Therapeutics Holdings Corp:intends to offer shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering.The shares of common stock and warrants to purchase shares of common stock are being offered as units.The shares of common stock and warrants will be immediately separable and will be issued separately.In connection with this offering, InVivo intends to grant the underwriters an option to purchase an additional 15% of the securities sold in the offering. All securities in the offering are being offered by InVivo.The offering is subject to market conditions and there can be no assurance as to whether the offering may be completed, or as to the actual size or terms of the offering.Raymond James & Associates, Inc. will act as the sole book-running manager in the offering.InVivo intends to use the net proceeds from this offering to fund ongoing clinical trials and for general corporate purposes.  Full Article

BRIEF-InVivo Therapeutics Appoints Richard Toselli As Chief Executive Officer

* INVIVO THERAPEUTICS ANNOUNCES APPOINTMENT OF RICHARD TOSELLI, M.D., AS PRESIDENT AND CHIEF EXECUTIVE OFFICER